HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Dr. McDermott on Long-Term Benefit With Nivolumab in RCC

David F. McDermott, MD, associate professor of Medicine, Harvard Medical School, staff physician, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses long-term follow-up results of treatment with nivolumab (Opdivo) for patients with renal cell carcinoma (RCC).

David F. McDermott, MD, associate professor of Medicine, Harvard Medical School, staff physician, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses long-term follow-up results of treatment with nivolumab (Opdivo) for patients with renal cell carcinoma (RCC).

Long-term outcomes from phase I and II studies of nivolumab demonstrate that the median overall survival was 22 months. However, with 48 months of follow-up, it was found that approximately one-third of patients were alive at 4 years and one-third were alive at 5 years. Compared with data from 5 to 10 years ago, these results are very encouraging, McDermott explains.

Longer follow-up will need to be conducted of the phase III study. However, McDermott says that an interesting point about these data is that it can impact a broader group of patients with RCC.